d3 Medicine and Viroclinics Biosciences inked a nonexclusive Memorandum of Understanding to provide an integrated solution to accelerate the preclinical and clinical development of drugs, biologicals, vaccines, and diagnostics targeting viral infectious diseases.

Viroclinics Biosciences will provide a range of preclinical and clinical diagnostic services, including high throughput serology, virology and molecular assays, phenotyping and genotyping in both translational studies and Phase I–IV clinical studies, and clinical trial logistics services.

d3 Medicine will formulate integrated development, clinical pharmacology and translational medicine strategies to fast-track preclinical development and define customized pharmacometric and quantitative pharmacological approaches to improve decision making and advance clinical and regulatory development.








This site uses Akismet to reduce spam. Learn how your comment data is processed.